by barry101 | Sep 21, 2023 | Press Releases
– Data readouts expected before year end – Previously reported preliminary efficacy data on its Phase 1B/2 clinical trial with Annamycin in monotherapy treatment of STS lung mets with >60% of the subjects exhibiting stable disease after two cycles of...
by barry101 | Sep 18, 2023 | Press Releases
– Annamycin continues to demonstrate no evidence of cardiotoxicity to date, now in a total of 62 subjects across three of the Company’s Annamycin clinical trials – Next generation anthracycline, Annamycin, has demonstrated both safety and promising...
by barry101 | Sep 14, 2023 | Press Releases
HOUSTON, Sept. 14, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Sep 5, 2023 | Press Releases
HOUSTON, Sept. 5, 2023 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses,...
by barry101 | Aug 11, 2023 | Press Releases
– Ongoing progress across ongoing clinical development programs with growing body of positive preclinical and clinical data – Released Clinical Trial Update press release yesterday providing the quarter’s update on its clinical activities –...
by barry101 | Aug 10, 2023 | Press Releases
– Announces successful completion of the Phase 1B portion of its Phase 1B/2 clinical trial Annamycin in combination with Cytarabine for the treatment of AML (MB-106) and opens the Phase 2 portion for recruitment – Announces a preliminary CR/CRi rate of 33%...
